# Jeffrey Weitz
Najpopularniejsze odcinki podcastów
Zaktualizowano:
jeffrey weitz is a Canadian bioscientist, currently the Canada Research Chair in Thrombosis and Endowed Chair in Cardiovascular Medicine at McMaster University.
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Navigating the Path to Next-Generation Anticoagulation Strategies: Rising to the Challenge of Unmet Needs in SSP and AF
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and t…
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Navigating the Path to Next-Generation Anticoagulation Strategies: Rising to the Challenge of Unmet Needs in SSP and AF
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and t…
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Navigating the Path to Next-Generation Anticoagulation Strategies: Rising to the Challenge of Unmet Needs in SSP and AF
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and t…
Balancing Infection and Thrombosis: Bispecific Antibodies and the Many Roles of HRG
In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Joshua Hill and Jeffery Weitz on their latest articles published in Blood. Dr. Hill and Dr. Michaelis discuss the evolving landscape of infection risk in adults receiving bispecific antibody therapies for advanced B‑cell malig…
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
WYSZUKIWARKA PODCASTÓW
Możesz skorzystać z naszej strony internetowej, aby wyszukiwać podcasty3,820,646i odcinki195,245,083według osób, miejsc lub tematów.
Inwestycja w wiedzę przynosi największe zyski, dlatego słucham podcastów.
‐ Benjamin "Llamacorn" Franklin
EDYTUJ
Dziękujemy za pomoc w aktualizowaniu podcastowej bazy danych.
